VPC-13566

CAS: 218464-59-6

Ref. 3D-TIA46459

Produktinformation

• Name: VPC-13566
• Marke: Biosynth
• Beschreibung: VPC-13566 is a novel drug that inhibits the production of an endogenous antigen. It binds to a specific molecule on the surface of prostate cancer cells and blocks the growth of these cells. VPC-13566 has been shown to be safe and effective in animal models, and it has been shown to be orally available with good pharmacokinetic properties. This drug is currently in clinical trials for prostate cancer treatment, but it may have potential for other types of cancer as well.

Chemische Eigenschaften

• Molekulargewicht: 258.3 g/mol
• Formel: C₁₈H₁₄N₂
• Reinheit: Min. 95%